Holen Sie sich die Stockscreener-App
1.17
0.43%
-0.00
Rein Therapeutics Inc Aktie (RNTX) Neueste Nachrichten
Rein Therapeutics Prices $50 Million Public Equity Offering - TipRanks
Rein Therapeutics (NASDAQ: RNTX) raises $50M, funds IPF trial into 2028 - Stock Titan
Rein Therapeutics, Inc.Common Stock (Nasdaq:RNTX) Stock Quote - The Chronicle-Journal
Rein Therapeutics (NASDAQ: RNTX) to sell 50M shares, nets ~$46.1M - Stock Titan
L. Lytton reports 4.5M shares in Rein Therapeutics (NASDAQ: RNTX) - Stock Titan
Rein Therapeutics stock dips after pricing $50M share offering - MSN
RNTX Slides As Rein Therapeutics Stock Tests New Lows - timothysykes.com
Rein Therapeutics Prices $50 Million Common Stock Offering; Shares Down Pre-Bell - Moomoo
Rein Therapeutics | EFFECT: Others - Moomoo
RNTX Stock Slides As Traders Eye Heavy Losses - timothysykes.com
Rein Therapeutics prices $50 million public offering at $1 - Investing.com
Rein Therapeutics prices $50 million public offering at $1 By Investing.com - Investing.com South Africa
Rein Therapeutics Inc prices public offering of 50 million shares at $1.00 per share for $50 million - marketscreener.com
Rein's $50M stock sale backs Phase 2 lung fibrosis study - Stock Titan
Rein Therapeutics' 50M-Share Offering Prices at $1 a Share - Moomoo
RNTX Ownership | REIN THERAPEUTICS INC (NASDAQ:RNTX) - ChartMill
RNTX (Rein Therapeutics) shares drop 12 percent after Q4 2025 EPS misses analyst estimates by a massive margin.Crowd Breakout Signals - Newser
Rein Therapeutics provides clinical trial update for Phase 2 ReNEW Study of LTI-03 in idiopathic pulmonary fibrosis - marketscreener.com
RNTX - Finviz
Rein Therapeutics Provides Clinical Trial Update For Phase 2 Renew Study Of Lti-03 In Idiopathic Pulmonary Fibrosis - TradingView
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis - ChartMill
Rein Therapeutics (RNTX) to sell 30M shares to fund LTI‑03 trial - Stock Titan
Is Rein Therapeutics (RNTX) stock testing important levels | Q4 2025: Profit DisappointsCommunity Sell Signals - Newser
Rein Therapeutics, Inc. 2025 Executive Compensation, Director Pay, and Governance Details (10-K/A) - Minichart
Rein Therapeutics (NASDAQ: RNTX) details 2025 pay, ownership in 10-K/A - Stock Titan
Rein Therapeutics : Amendment to Annual Report (Form 10-K/A) - marketscreener.com
Rein Therapeutics Inc. (NASDAQ:RNTX) Short Interest Down 51.4% in April - MarketBeat
India's HCLTech forecasts weak annual revenue growth as clients rein in discretionary spends - Yahoo Finance
Is Rein Therapeutics (RNTX) stock gaining strength (Momentum Building) 2026-04-20Fast Rising Picks - Xã Vĩnh Công
RNTX Forecast, Price Target & Analyst Ratings | REIN THERAPEUTICS INC (NASDAQ:RNTX) - ChartMill
KCK LTD. Significantly Reduces Stake in Sight Sciences Inc - GuruFocus
Why Rein Therapeutics Inc. stock is a must watch in 20262026 Earnings Surprises & Stock Timing and Entry Methods - bollywoodhelpline.com
What are bearish arguments for Rein Therapeutics (RNTX) Stock | Price at $1.54, Up 0.65%Investment Picks - Newser
FY2026 EPS Estimate for Rein Therapeutics Lowered by Analyst - defenseworld.net
PTN PE Ratio & Valuation, Is PTN Overvalued - Intellectia AI
Stock List: Research Stocks from Around the World - GuruFocus
BLRX PE Ratio & Valuation, Is BLRX Overvalued - Intellectia AI
RNTX Should I Buy - Intellectia AI
Rein 2026 10-K Report: Business Overview, Risk Factors, Pipeline, Competition, and Strategic Partnerships - Minichart
Rein Therapeutics 10-K: $0 Revenue, $0 Gross Profit; Net Loss $49.9M - TradingView — Track All Markets
Rein Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Rein Therapeutics (NASDAQ: RNTX) 10-K shifts focus to LTI-03 and flags 2026 funding needs - stocktitan.net
Rein Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
If You Invested $1,000 in Neuphoria Therapeutics Inc (NEUP) - Stock Titan
Rein Therapeutics Inc. (RNTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aug Decliners: What makes Rein Therapeutics Inc stock attractive today2026 Analyst Calls & High Accuracy Swing Trade Signals - baoquankhu1.vn
Risk Off: Can Rein Therapeutics Inc beat the S P 5002026 AllTime Highs & Smart Investment Allocation Insights - baoquankhu1.vn
Update Recap: Can Rein Therapeutics Inc sustain earnings growthEarnings Trend Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Returns Recap: Can RenovoRx Inc expand its profit margins2026 Growth vs Value & Accurate Intraday Trade Tips - baoquankhu1.vn
Will Rein Therapeutics Inc. stock outperform international peersPortfolio Performance Summary & Daily Chart Pattern Signal Reports - Naître et grandir
What technical signals suggest for IDAI stockBond Market & Daily Stock Trend Watchlist - Naître et grandir
How Roundhill ETF Trust Roundhill AMZN stock valuation compares with sector2025 Sector Review & Long-Term Safe Investment Plans - Naître et grandir
Why BILL stock appeals to dividend investorsJuly 2025 Recap & AI Powered Market Entry Strategies - Naître et grandir
Rein Therapeutics Secures Funding and Advances Key Clinical Trial () - aktiencheck.de
With FDA hold lifted, IPF clinical trial of LTI-03 begins dosing patients - Pulmonary Fibrosis News
Rein Therapeutics doses first patient in IPF trial for LTI-03 - Investing.com Canada
Rein Therapeutics doses first patient in phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis - marketscreener.com
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis - GlobeNewswire
Rein Therapeutics Raises $2.3 Million in Private Unsecured Notes With 20% OID, Due by Jun 30, 2026 - TradingView
Chet Holmgren x Nike KD 18 "Thunder & Reign" Releases March 13th - Sneaker Bar Detroit
RNTX Technical Analysis & Stock Price Forecast - Intellectia AI
Rein Therapeutics Inc. announced that it has received $2.3 million in funding - marketscreener.com
5.78%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):